Shareholder voteRegulatory filing
What was reported
On June 3, 2026, Beam Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 17, 2026.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jun 8, 2026 · Open the source ↗
What the evidence supports
Beam Therapeutics told the SEC (Form 8-K, Item 5.07) that its shareholders voted on matters put to them, and what the outcome was. The filing gives Jun 3, 2026 as the date of the earliest event reported.
What remains unknown
How individual shareholders voted, and what the company will do next beyond what it disclosed.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.07 textOn June 3, 2026, Beam Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 17, 2026.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jun 8, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Beam Therapeutics reports results of a shareholder vote (Form 8-K, Item 5.07)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.